Zobrazeno 1 - 10
of 11
pro vyhledávání: '"Lily Q. Li"'
Autor:
Franck Morschhauser, Kamal Bouabdallah, Stephan Stilgenbauer, Catherine Thieblemont, Sophie de Guibert, Florian Zettl, Lawrence M. Gelbert, P. Kellie Turner, Siva Rama Prasad Kambhampati, Li Li, Lily Q. Li, Sean Buchanan, Susana Barriga, Melissa M. Bear, Martin Wilhelm, Georg Hess
Publikováno v:
Haematologica, Vol 106, Iss 3 (2020)
Externí odkaz:
https://doaj.org/article/d1330710d90f43f6a096ac0bba1735f1
Autor:
Geoffrey I. Shapiro, Patrick Y. Wen, Keith T. Flaherty, Edward M. Chan, Damien M. Cronier, Martin Frenzel, Lily Q. Li, Palaniappan Kulanthaivel, Ricardo Martinez, Tuan S. Nguyen, Angie D. Fulford, Andrew E. Schade, Richard P. Beckmann, Aejaz Nasir, John F. Hilton, Drew W. Rasco, Muralidhar Beeram, Kyriakos P. Papadopoulos, Leena Gandhi, Jonathan W. Goldman, Anthony W. Tolcher, Sara M. Tolaney, Lee S. Rosen, Amita Patnaik
Supplementary Table 1. Summary of 33 Patients Treated with Abemaciclib in Dose Escalation. Supplementary Table 2. Baseline patient and disease characteristics. Supplementary Table 3. Possibly related treatment-emergent adverse events (>10% all grades
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::36991b4fd4f6f7c7f083e22b6e2c0a5d
https://doi.org/10.1158/2159-8290.22531521
https://doi.org/10.1158/2159-8290.22531521
Autor:
Patricia Pozo-Rosich, Holland C. Detke, Shufang Wang, David Doležil, Lily Q. Li, Sheena K. Aurora, Uwe Reuter
Publikováno v:
Scientia
Galcanezumab; Chronic migraine; Preventive treatment Galcanezumab; Migraña crónica; Tratamiento preventivo Galcanezumab; Migranya crònica; Tractament preventiu Background Galcanezumab, a monoclonal antibody to calcitonin gene-related peptide, was
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a3445338f363b3d64be27fa84f4c0fe5
https://doi.org/10.1080/03007995.2022.2059975
https://doi.org/10.1080/03007995.2022.2059975
Autor:
Sophie de Guibert, P. Kellie Turner, Kamal Bouabdallah, Catherine Thieblemont, Florian Zettl, Siva Rama Prasad Kambhampati, Franck Morschhauser, Li Li, Sean Buchanan, Stephan Stilgenbauer, Lily Q. Li, Susana Barriga, Lawrence M. Gelbert, Martin Wilhelm, Georg Hess, Melissa M. Bear
Publikováno v:
Haematologica
Haematologica, Ferrata Storti Foundation, 2020, ⟨10.3324/haematol.2019.224535⟩
Haematologica, Ferrata Storti Foundation, 2020, ⟨10.3324/haematol.2019.224535⟩
International audience
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::29c7d227d503893449b11894361ddc8a
https://doi.org/10.3324/haematol.2019.224535
https://doi.org/10.3324/haematol.2019.224535
Autor:
Stewart J. Tepper, Jessica Ailani, Janet H. Ford, Russell M. Nichols, Lily Q. Li, Phebe Kemmer, Austin L. Hand, Antje Tockhorn-Heidenreich
Publikováno v:
Clinical drug investigation. 42(3)
Patients with migraine and prior preventive treatment failures have a significant burden on quality of life and disability. The CONQUER study evaluated the effects of galcanezumab on patient functioning, disability, and health status in episodic or c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a8e695857c5088433337fcd225aa5e98
https://pubmed.ncbi.nlm.nih.gov/35254628
https://pubmed.ncbi.nlm.nih.gov/35254628
Autor:
Stewart J. Tepper, Jessica Ailani, Janet H. Ford, Russell M. Nichols, Lily Q. Li, Phebe Kemmer, Austin L. Hand, Antje Tockhorn-Heidenreich
Publikováno v:
Clinical Drug Investigation. 42:277-277
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::013070b99f0f76375ba3f18242b73a4e
https://doi.org/10.1007/s40261-022-01123-z
https://doi.org/10.1007/s40261-022-01123-z
Autor:
Stewart J. Tepper, Katie Fawcett, Shufang Wang, Russell M Nichols, Jessica Ailani, Lily Q. Li, Janet H. Ford
Publikováno v:
Revue Neurologique. 177:S28
Introduction L’etude CONQUER de phase 3 randomisee, en double aveugle, controlee vs placebo a evalue l’efficacite/la tolerance de GMB chez des patients atteints de migraine difficile a traiter. Objectifs Evaluer l’efficacite du GMB sur la quali
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::28759963487f9c0423bdfa58fcc592f6
https://doi.org/10.1016/j.neurol.2021.02.141
https://doi.org/10.1016/j.neurol.2021.02.141
Autor:
Lily Q. Li, Jennifer Leohr, Claire F. Verschraegen, Anthony W. Tolcher, Eric H. Westin, Anthony J. Olszanski, Anna McGlothlin, Muralidhar Beeram, Roger B. Cohen, Scott M. Hynes, Kyriakos P. Papadopoulos, Daphne L. Farrington, Montaser Shaheen, Aimee Bence Lin, Amita Patnaik, Howard A. Burris, Jeffrey R. Infante
Publikováno v:
Cancer chemotherapy and pharmacology. 79(2)
This first-in-human report examined the recommended Phase 2 dose and schedule of litronesib, a selective allosteric kinesin Eg5 inhibitor. Two concurrent dose-escalation studies investigated litronesib across the dose range of 0.125–16 mg/m2/day, e
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f8d138c3b8b49f4afdc14893af5b20f9
https://pubmed.ncbi.nlm.nih.gov/28097385
https://pubmed.ncbi.nlm.nih.gov/28097385
Autor:
Richard P. Beckmann, David Xiaohui Wang, Kamal Bouabdallah, Sophie de Guibert, Stephan Stilgenbauer, Florian Zettl, Lawrence M. Gelbert, Edward M. Chan, Ji Lin, Lily Q. Li, Franck Morschhauser, Patrick Brueck, Catherine Thieblemont, Michael Pfreundschuh, Damien M. Cronier, Charles W. Caldwell, Martin Wilhem, Georg Hess, Marjo Hahka-Kemppinen, Martin Wolf
Publikováno v:
Blood. 124:3067-3067
Background: Mantle cell lymphoma (MCL) is characterized by a recurrent chromosomal translocation t(11;14) that leads to aberrant expression of Cyclin D1 which, together with cyclin dependent kinases 4 and 6 (CDK4/6), inhibits the retinoblastoma (Rb)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8506739d8e6575372a0b3f59138be8ea
https://doi.org/10.1182/blood.v124.21.3067.3067
https://doi.org/10.1182/blood.v124.21.3067.3067
Autor:
Kyriakos P. Papadopoulos, Drew W. Rasco, Jonathan W. Goldman, Patrick Y. Wen, Sara M. Tolaney, Amita Patnaik, Leena Gandhi, Lee S. Rosen, Keith T. Flaherty, Damien M. Cronier, Anthony W. Tolcher, Muralidhar Beeram, Palaniappan Kulanthaivel, Geoffrey I. Shapiro, Martin Frenzel, Edward M. Chan, Scott P. Myrand, Lily Q. Li
Publikováno v:
Cancer Research. 74:CT232-CT232
LY2835219 is a novel cell cycle inhibitor selective for the cyclin-dependent kinases CDK4 and CDK6 (CDK4/6), which act in a protein complex with D-type cyclins to enable G1 to S cell cycle progression. Preclinical models indicate this complex plays a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::11e6fd1b7950be13e0b06bca8dd8e51e
https://doi.org/10.1158/1538-7445.am2014-ct232
https://doi.org/10.1158/1538-7445.am2014-ct232